We serve Chemical Name:3-Methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol CAS:507462-88-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-Methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol
CAS.NO:507462-88-6
Synonyms:3-Methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol
Molecular Formula:C13H19BO4
Molecular Weight:250.09900
HS Code:2934999090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:47.92000
Exact Mass:250.13800
LogP:1.70000
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 3-Methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-Methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol Use and application,3-Methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol technical grade,usp/ep/jp grade.
Related News: CHMP on Friday also announced that Roche pulled its Tecentriq application in triple-negative breast cancer after it noted that the EMA said the results from a late-stage trial do not favor the drug’s benefit-risk calculation in this indication. Methyl-17β-acetoxy-3-methoxy-1,3,5(10)-oestratrien-16-ylidenacetat manufacturers The booster campaign, with shots administered by health maintenance organisations, will effectively turn Israel into a testing ground for a third dose before approval by the U.S. Food and Drug Administration (FDA). Ergoline-8-acetic acid, 6-propyl-, hydrazide, (8b)- suppliers The pivotal TULIP (Treatment of Uncontrolled Lupus via the Interferon Pathway) phase III programme includes two trials, TULIP-1 and TULIP-2, that evaluated the efficacy and safety of anifrolumab versus placebo. N-(ethoxycarbonyl)noroxycodone vendor & factory.